Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
Published in Business Wire on January 3, 2023
Gilead Sciences and EVOQ Therapeutics announced a collaboration and licensing agreement to advance EVOQ’s proprietary technology for the treatment of rheumatoid arthritis and lupus. Congratulations to MCIDT affiliate Dr. James Moon for his involvement in the collaboration! Read more here.